01

UCB's Galvokimig Advances in Atopic Dermatitis Pipeline

UCB's atopic dermatitis candidate galvokimig cleared transcriptomic and biomarker analyses, per The Dermatology Digest's AD Pipeline Watch, advancing the molecule toward a clinical readout.